Check for updates

OPEN ACCESS

EDITED BY Renjith Thomas, Mahatma Gandhi University, India

REVIEWED BY

Emmanuel Silva Marinho, State University of Ceará, Brazil Dusan Dimic, University of Belgrade, Serbia

*CORRESPONDENCE

Amany Belal, I a.belal@tu.edu.sa, I abilalmoh1@yahoo.com Eun Joo Roh, I r8636@kist.re.kr

RECEIVED 29 April 2024 ACCEPTED 14 June 2024 PUBLISHED 10 July 2024

CITATION

Belal A, Elballal MS, Al-Karmalawy AA, Hassan AHE, Roh EJ, Ghoneim MM, Ali MAM, Obaidullah AJ, Alotaibi JM, Shaaban S and Elanany MA (2024), Exploring the sedative properties of natural molecules from hop cones (*Humulus lupulus*) as promising natural anxiolytics through GABA receptors and the human serotonin transporter. *Front. Chem.* 12:1425485. doi: 10.3389/fchem.2024.1425485

COPYRIGHT

© 2024 Belal, Elballal, Al-Karmalawy, Hassan, Roh, Ghoneim, Ali, Obaidullah, Alotaibi, Shaaban and Elanany. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are

credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Exploring the sedative properties of natural molecules from hop cones (*Humulus lupulus*) as promising natural anxiolytics through GABA receptors and the human serotonin transporter

Amany Belal¹*, Mohammed S. Elballal², Ahmed A. Al-Karmalawy^{3,4}, Ahmed H. E. Hassan⁵, Eun Joo Roh^{6,7}*, Mohammed M. Ghoneim⁸, Mohamed A. M. Ali^{9,10}, Ahmad J. Obaidullah¹¹, Jawaher M. Alotaibi¹¹, Salwa Shaaban^{12,13} and Mohamed A. Elanany¹⁴

¹Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia, ²Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Cairo, Egypt, ³Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta, Egypt, ⁴Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt, ⁵Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, ⁶Chemical and Biological Integrative Research Center, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea, ⁷Division of Bio-Medical Science and Technology, University of Science and Technology, Daejeon, Republic of Korea, ⁸Department of Pharmacy Practice, College of Pharmacy, Almaarefa University, Ad Diriyah, Saudi Arabia, ⁹Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia, ¹⁰Department of Biochemistry, Faculty of Science, Ain Shams University, Riyadh, Saudi Arabia, ¹²Department of Microbiology and Immunology, Faculty of Pharmacy, Suef University, Beni-Suef, Egypt, ¹³Department of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia, ¹⁴Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Cairo, Egypt

This research work aimed to identify the main components that are responsible for the sedative properties of hop cones and allocate their targets. This investigation was performed through molecular docking, molecular dynamic simulations, root mean square fluctuation (RMSF) analysis, and DFT calculation techniques. The tested compounds from *Humulus lupulus* were compared to diazepam and paroxetine. Molecular docking showed that two-thirds of the compounds had a good affinity to gamma-aminobutyric acid (GABA), outperforming diazepam, while only three surpassed paroxetine on the SERT. Compounds 3,5-dihydroxy-4,6,6-tris(3-methylbut-2-en-1-yl)-2-(3-methylbuta noyl)cyclohexa-2,4-dien-1-one (**5**) and (*S*,*E*)-8-(3,7-dimethylocta-2,6-dien-1-yl)-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one (**15**) showed stable

binding and favorable energy parameters, indicating their potential for targeting GABA receptors and the SERT. This study provides a basis for future clinical research on these promising compounds.

KEYWORDS

natural molecules, hop cones, natural anxiolytics, DFT, molecular dynamics, RMSF analysis, molecular docking

1 Introduction

Anxiety is pathologic when it becomes maladaptive, permanent, and unmanageable and interferes with daily life. The current standard of care for anxiety disorders is based mostly on psychotherapy. Medications for anxiety disorders are now available, but they fall short of ideal in terms of efficacy and acceptability. Noncompliance, inadequate response to treatment, and relapse are serious problems for individuals who obtain treatment. Collectively, new effective methods for treating anxiety and associated diseases are desperately needed (Sartori and Singewald, 2019).

Serotonin (5-HT), a well-known neurotransmitter involved in regulating emotions, plays a crucial function in the neurobiology of anxiety (Zangrossi et al., 2020). The serotonin transporter (SERT) ends serotonergic signaling by actively transporting the neurotransmitter back into the presynaptic neurons in a sodiumand chloride-dependent fashion (Holmes et al., 2003). The SERT serves as a target for antidepressant and psychostimulant medications, which inhibit reuptake and extend the duration of neurotransmitter signaling. Selective serotonin reuptake inhibitors such as paroxetine, escitalopram, sertraline, and fluoxetine, are currently first-line treatment medications for most anxiety disorders, with a superior benefit/risk ratio than any other form of the available pharmacotherapy (Sartori and Singewald, 2019; Gosmann et al., 2021).

Similarly, gamma-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the central nervous system, assumes paramount importance in anxiety regulation (Kalueff and Nutt, 2007; Gauthier and Nuss, 2015). GABAergic neurotransmission, chiefly mediated through GABA-A receptor subtypes, orchestrates anxiolytic effects via dampening excitatory neuronal activity (Möhler, 2012). Pharmacological agents such as benzodiazepines (diazepam) potentiate GABA receptor function, eliciting sedative and anxiolytic responses (Inada et al., 2003). Nonetheless, protracted usage of benzodiazepines entails risks of tolerance and dependence, prompting exploration of alternative medications like gabapentinoids, which also modulate the GABA system. Therapeutic interventions targeting GABA receptors aspire to restore neural equilibrium, alleviate anxiety symptomatology, and ameliorate overall mental wellbeing (Hollister, 1981; Michelini et al., 2007).

Plants and their derivatives make up a significant portion of the human diet. Exploring the healing effects of plants should thus remain the primary focus of ongoing research due to their little or no negative side effects. Furthermore, synergistic effects can significantly improve their action or the action of current medications and therapies (Knez Hrnčič et al., 2019). *Humulus lupulus L.* (common hop) is a perennial herbaceous liana and one of three Humulus species in the Cannabaceae family. Strobili (hops) are cone-like structures in female plants (Korpelainen and Pietiläinen, 2021). The hop plant, seen in Figure 1, has been in continuous use for years, if not millennia, primarily as an antimicrobial component in beer. It is now used to treat agitation, anxiety, and sleep issues (Heinlein et al., 2014; Hrnčič et al., 2019). The first isolated phytoconstituent was lupulin, and it was considered almost a specific remedy for scrofula, struma, and various skin diseases (REILLY, 1906). In addition to lupulin, hop contains a variety of phytochemicals including xanthohumol, humulone, lupulone, 8prenylnaringenin, and myrcene, which contribute to its antioxidant and antimicrobial properties. Due to the abundance of dietary phytochemicals in H. lupulus that have medical uses, including antibacterial, antioxidant, anticancer, antiplatelet, antidiuretic, anti-inflammatory, and sedative effects, this plant has received special attention (Tronina et al., 2020). To confirm these physiological effects, several in vitro and in vivo investigations have been carried out (Heinlein et al., 2014). Research driven by these effects revealed that these neurological effects may be partially mediated through the modulation of GABA receptors (Benkherouf et al., 2020; Carbone and Gervasi, 2022).

Encouraged by these data, we explored the potential of various phytochemicals (Figure 2) isolated from *H. lupulus L.* As such, after a literature search, we compiled 15 compounds and studied their effects on GABA and the human serotonin transporter (SERT) through multiple *in silico* techniques.



FIGURE 1 Used parts of *Humulus lupulus L*. retrieved from https://en. wikipedia.org/wiki/Humulus_lupulus.



2 Materials and methods

2.1 Molecular docking

GABA and SERT receptors were downloaded from the Protein Data Bank (PDB IDs: 6X3X and 5I6X, respectively) (Coleman et al., 2016; Kim et al., 2020). A literature search was performed to identify isolated compounds from *Humulus lupulus L.*, and PubChem (https://pubchem.ncbi.nlm.nih.gov/) was accessed to obtain the smiles (Kim et al., 2021). The compounds were compiled into a database for processing, in addition to the receptors, and all were prepared and optimized using the standard protocol of the Autodock Vina. Energy minimization was performed using M.G. L. tools, and the active site was set to the pocket surrounding the cocrystalized ligands (diazepam and paroxetine) (Trott and Olson, 2010). Docking was performed using the Autodock vina with its scoring function. The docking site was selected as 24*24*24 Å surrounding co-crystallized ligands. Validation was achieved by re-docking of the co-crystallized ligands into their binding pocket, followed by calculating the RMSD between poses. Biovia DS Visualizer was used to analyze the docking results as well (Dassault Systèmes, 2021; Belal et al., 2022a).

2.2 Dynamic simulations and calculations

The Schrödinger Desmond package was used for molecular dynamics simulations of free proteins and their complexes (Bowers et al., 2006). Preparation was done using the "OPLS4" force field as described before. The system was constructed using "TIP3P" water molecules in an orthorhombic box (Lu et al., 2021). The systems underwent simulation under the default settings of "NPT" ensemble (300 K and 1.01325 bar) for 50 ns for each simulation, followed by an interaction analysis to calculate the RMSD, RMSF, and other properties (Schrödinger, 2021; Belal et al., 2022b).



2.3 Molecular mechanics-generalized Born surface area calculations

The MM-GBSA technique was used to compute the binding free energy of the studied protein–ligand complexes, which integrated molecular mechanics (MM) force fields with a generalized Born and surface area continuum solvation model using the Schrodinger Prime package (Jacobson et al., 2004; Belal et al., 2022c). Contributions from molecular mechanics energies and polar and non-polar solvation were estimated using the equation $\Delta E_B = \Delta E_C - (\Delta E_P + \Delta E_L)$, where ΔE_B is the calculated binding free energy of the complex, ΔE_C is the binding free energy of the complex, ΔE_P is the binding free energy of the protein, and ΔE_L is the binding free energy of the ligand (Dimić et al., 2019; Jupudi et al., 2022; Jevtovic et al., 2023).

2.4 Density functional theory calculations

The Spartan '14 program was used to perform quantum chemistry calculations using the DFT method. Spartan '14 was used to display all of the data files. The density functional theory (DFT) at 6-311G++(d,p) basis set/B3LYP approach was utilized to optimize the organic chemical structure of the compound under investigation, and Chem3D 15.0 software was used to create the original chemical structure (Legler et al., 2015).

3 Results and discussion

3.1 Molecular docking

The Autodock Vina program was used in the current docking study. Validation of docking accurately reproduced the binding conformation of the co-crystallized ligands with GABA and human serotonin transporter receptors (PDB IDs: 3X6X and 5I6X, respectively). In both cases, the monomer of the receptor was obtained and processed for subsequent analysis. The RMSD values were calculated between the co-crystallized poses and the docked poses of the same ligands, and the results revealed minor deviations of 0.17 and 0.33 Å for GABA and 5-HT, respectively Figure 3. These results indicated the validity of the docking studies, and the compounds were docked accordingly. As shown in Table 1, the compounds exhibited negative binding scores, indicating the favorability of their binding to both GABA and SERT receptors. Additionally, for comparative analysis, both diazepam and paroxetine were used as references for both targets.

3.1.1 Molecular docking against GABA receptors

Analysis of the binding of diazepam (Figure 4) revealed its low score (-6.83 kcal/mole) due to the formation of several hydrophobic interactions through its chlorophenyl and phenyl moieties with Ile228, Pro233, Met261, Leu269, Met286, and Phe289, in addition to two hydrogen bonds with Ile228 and Thr262. Most of the compounds (two-thirds) achieved higher scores than diazepam, with the top-scoring compounds being 5, 14, 15, and 10 (-9.23, -8.90, -8.76, and -8.62 kcal/mole, respectively).

The hydrophobic groups in our top three compounds played an important role in their binding, as shown in Figure 5. Similar to diazepam, all top three compounds formed many hydrophobic interactions with one or two hydrogen bonds. Compound 5's superior binding is attributed to its three 3methylbut-3-enyl moieties that exclusively interacted with Ile228, Met236, Leu240, Val258, Met286, Phe289, and Phe293 through twelve hydrophobic bonds. Additionally, two hydrogen bonds were observed as well with Pro233 and Thr266 through two carbonyls.

Similarly, the same amino acids formed hydrophobic bonds with compound 14 and one hydrogen bond with Arg269. Unlike compound 5, compound 14 possessed only two 3-methylbut-3enyl moieties, which contributed with only six hydrophobic interactions. However, it was compensated through its central chromone and terminal phenyl rings with additional three bonds. Compound 15 behaved similarly to 14; its central chromone and

No.	Compound chemical name	CID	GABA	SERT				
1	(E)-3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxy-3-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one	6443339	-7.53	-7.42				
2	(E) - 1 - (2, 4 - dihydroxy - 6 - methoxy - 3 - (3 - methylbut - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl) - 3 - (4 - hydroxyphenyl)prop - 2 - en - 1 - one - 2 - en - 1 - yl)phenyl)prop - 2 - en - 1 - one - 2 - en - 2 - e	639665	-8.1	-8.15				
3	(1E,4E,8E)-2,6,6,9-tetramethylcycloundeca-1,4,8-triene	5281520	-6.04	-5.95				
4	(1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo [7.2.0]undec-4-ene	5281515	-6.16	-5.92				
5	3,5-dihydroxy-4,6,6-tris(3-methylbut-2-en-1-yl)-2-(3-methylbutanoyl)cyclohexa-2,4-dien-1-one	68051	-9.23	-9.05				
6	3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)-2-(3-methylbutanoyl)-4-(4-methylpent-3-enoyl)cyclopent-2-en-1-one	93090	-8.39	-8.02				
7	(4Z,8Z)-2,6,6,9-tetramethylcycloundeca-4,8-dien-1-one	101297706	-5.84	-6.33				
8	3,5,6-trihydroxy-2-isobutyryl-4,6-bis(3-methylbut-2-en-1-yl)cyclohexa-2,4-dien-1-one	196915	-8.19	-8.02				
9	7-methyl-3-methyleneocta-1,6-diene	31253	-5.42	-5.49				
10	5,7-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)chroman-4-one	513197	-8.62	-8.52				
11	7-hydroxy-2-(4-hydroxyphenyl)-5-methoxy-8-(3-methylbut-2-en-1-yl)chroman-4-one	480764	-8.29	-8.14				
12	(R)-3,5,6-trihydroxy-4,6-bis(3-methylbut-2-en-1-yl)-2-(3-methylbutanoyl)cyclohexa-2,4-dien-1-one	442911	-8.33	-7.99				
13	(S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one	155094	-8.04	-7.76				
14	(R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-6,8-bis(3-methylbut-2-en-1-yl)chroman-4-one	124035	-8.90	-8.74				
15	(S,E)-8-(3,7-dimethylocta-2,6-dien-1-yl)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one	6475921	-8.76	-9.12				
	Diazepam	3016	-6.83					
	Paroxetine	43815		-8.71				
CID: PubChem identification code								

TABLE 1 Docking results of hop cones compounds against GABA and SERT receptors in kcal/mole.



terminal phenyl rings oriented toward the same amino acids. The main difference is the hydrophobic counterpart, the 3,7-dimethyloctane-2,6-dienyl group. This group's length forces the orientation of the chromone ring to flip to accommodate the binding pocket. This in turn brings the central chromone ring

in close proximity to Ile228 and GLN229 to form hydrogen bonds through the hydroxyl group Figure 6. Finally, compound 10 behaved similarly to 14 but with only one main hydrophobic moiety (3-methylbut-3-enyl), which explains its inferior score compared to that of the others.





3.1.2 Molecular docking against SERT receptors

On the other hand, paroxetine (Figure 7) exhibited a score of -8.71 kcal/mole and interacted with Tyr95, Ala169, Ile172, Ala173, Phe341, and Ser438 through hydrophobic interactions with its fluorophenyl and 1,3-benzodixole moieties in addition to three hydrogen bonds with Ala69, Ala169, and Ser336 mainly through the piperidine ring. Unlike previously, only three compounds exhibited higher scores than paroxetine, with the

top-scoring compounds being 15, 5, and 14 (-9.12, -9.05, and -8.74 kcal/mole, respectively).

Again, the presence of hydrophobic alkenyl chains like 3methylbut-3-enyl and 3,7-dimethyloctane-2,6-dienyl groups impacted the binding of the compounds. These chains formed several hydrophobic interactions with Ile172, Tyr176, and Phe335 (Figure 8). Overall, the three compounds possessed these chains, but the individual differences can be attributed to the difference in hydrogen bonding. Individually, compound 15's strongest binding was attributed to the three additional





hydrogen bonds with Tyr95, Ala169, and Gly338 through its three hydroxy groups on the coumarin and terminal phenyl groups. Although compound 5 formed only one hydrogen bond with Tyr175, its ability to bond via more hydrophobic interactions with other amino acids (Leu99, Trp103, Ile179, and Phe341) compensated for this shortcoming and explained



the moderate decrease in its score. Alternatively, the lack of some hydrophobic interactions explained how compound 14 achieved poorer results, despite two hydrogen bonds with Arg104 and Gln332.

The interesting results of compounds 5 and 15 over both targets established their potential for further analysis throughout our study.

3.2 Dynamic simulations and calculations

Molecular dynamic simulations extensively analyzed the binding modes and stability under realistic physiological conditions. Using the Schrodinger Maestro suite, the proteins with and without compounds 5 and 15 were simulated for 50 ns. Additionally, diazepam and paroxetine were simulated with their respective proteins for comparison. Afterward, the simulation trajectories were analyzed, and several attributes were calculated, such as the root mean square deviation (RMSD) of the protein–ligand complex for determination of the binding interaction stability, the RMSD of ligands to evaluate the conformational changes ligands undergo over the estimated simulation process, as well as the root mean square fluctuation (RMSF) of the amino acid residues and their contact with ligands.

3.2.1 RMSD analysis

The free GABA protein shows relative homogeneity in behavior, as demonstrated by the RMSD's initial consistency around 2 Å for the first 25 ns, followed by a plateau at 2.80 Å (Figure 9). After introducing diazepam, the RMSD behavior was lowered slightly to

approximately 2.50 Å. The effect of binding of both compounds 5 and 15 on the protein can be seen similarly, with the RMSD fluctuating at approximately 2.40 and 2.90 Å, respectively. Moreover, the inspection of both ligands' conformational motion showed that compounds 5 and 15 maintain high conservation and stability, evidenced by the uniform RMSD at 1.00 and 0.50 Å, respectively.

Similarly, the free SERT showed relative homogeneity in behavior, as demonstrated by the RMSD's initial consistency around 2.10 Å, followed by a plateau at 2.50 Å (Figure 10). The binding of paroxetine altered the RMSD behavior, lowering it slightly to approximately 2.40 Å. The binding of compound 15 affected the protein's RMSD, similar to that of paroxetine lowering, while compound 5 decreased it slightly to approximately 2.10 Å. Moreover, the inspection of both ligands' conformational motion showed that compounds 15 and 5 maintain relative conformational stability with a uniform RMSD at 2.40 and 1.10 Å, respectively.

3.2.2 RMSF analysis

The RMSF plots for the free proteins and their complexes with both compounds were assessed to expand our understanding of their interactions throughout the 50-ns simulation (Figures 11, 12). The RMSF measures the flexibility of each residue in the protein, providing insights into how ligand binding affects protein dynamics.

For the free GABA protein, the RMSF plots indicated a high degree of flexibility, suggesting that the protein exhibits significant conformational freedom in the absence of a ligand. However, upon binding with diazepam, compounds **5** and **15** showed a marked reduction in the fluctuations of several residues. This indicates that these ligands stabilize the protein structure by restraining its





dynamic behavior. Similarly, the RMSF analysis of the SERT revealed high residue flexibility in its unbound state. The introduction of paroxetine, compound 5, and compound 15 led to decreased fluctuations in SERT residues, suggesting that these

ligands also stabilize the transporter structure, reducing its conformational flexibility.

These observations align with previous molecular docking results, which suggested strong binding interactions between



TABLE 2 MM-GBSA results of compounds 5 and 15 when complexed with GABA and SERT receptors.

	GABA				SERT				
	5		15		5		15		
	Start	End	Start	End	Start	End	Start	End	
$\Delta G_{\rm Binding}$	-86.79	-70.87	-72.12	-74.69	-63.85	-69.10	-73.16	-69.66	
ΔG Binding Coulomb	-12.06	-3.94	-12.87	-12.04	-8.27	-4.02	-13.48	-14.75	
ΔG Binding (NS)	-92.82	-76.56	-82.54	-77.26	-68.99	-74.77	-80.68	-74.33	
ΔG Binding (NS) Coulomb	-13.40	-3.97	-13.77	-11.00	-7.46	-4.15	-13.58	-16.76	

ligands and proteins. The reduction in residue fluctuations upon ligand binding supports the stability of the interactions.

3.2.3 MM-GBSA calculations

Molecular mechanics-generalized Born surface area is one of the most frequent methods for determining the binding free energy (MM-GBSA). This approach integrates molecular mechanics (MM) force fields with the generalized Born (GB) and surface area (SA) continuum solvation model to provide an estimation of the binding free energies, offering insights into the stability and affinity of the complexes. The calculations were conducted using the Schrödinger Prime package, a comprehensive tool for performing these sophisticated computations. The lower the predicted binding free energy of a ligand-protein complex, the more stable the complex will be, and the greater the ligand's activity and potency. Both complexes showed stable binding throughout the dynamic simulation, as demonstrated by the energy scores in Table 2.

3.3 DFT calculations

The DFT/B3LYP approach was used in the current work to perform quantum chemical computations to optimize the selected structures. The DFT (B3LYP) method with the 6-311G++(d,p) basis set was applied in this test. The optimized structure and its HOMO and LUMO values are represented in Figure 13. The HOMO energy expresses the ability of the compound to give electrons as an electron donor. It is localized mainly on the two 3-methylbut-2-en-1-yl moieties of compound 5 on carbon 6. This electronic enrichment explains their hydrophobic capacity to form multiple interactions within SERT and GABA receptors, as previously shown in docking. It was mostly localized on the dihydroxyphenyl ring with its dangling eight-carbon substituent in compound 15. This also impacted the hydrophobic binding of the alkenyl tail and allowed for better availability of the hydroxyl group to form hydrogen bonds.



TABLE 3 DFT	calculation	results	of	compounds	5	and	15
-------------	-------------	---------	----	-----------	---	-----	----

	Energy (au)	Energy solvation (kj/Mol)	E Homo (ev)	E Lumo (ev)	Dipole moment (debye)	No. of conformers
5	-1,314.87133	-5.58	-6.59	-1.82	3.65	157,464
15	-1,345.97759	-63.96	-6.06	-1.45	3.54	5,184

On the other hand, the LUMO energy displayed by a site can act as an electron attractor, i.e., electron acceptors, due to vacant orbitals and localized at the central six-membered ring(s) of compounds **5** and **15**. Similarly, the electrostatic potential maps of the compounds showed areas with electron localization throughout the molecules, with red and blue representing electron-rich (negative) and -deficient (positive) localizations, respectively. Finally, the DFT calculations revealed favorable energetic parameters for the selected compounds Table 3.

4 Conclusion

The sedative properties of hop cones (*H. lupulus L.*) have been extensively exploited in herbal remedies for a long time. Despite this, there is no research to isolate the main component responsible for these properties and allocate its target. Thus, we analyzed the isolated compounds from *H. lupulus L.* and studied their effects compared to those of two widely used drugs, diazepam and paroxetine, using

multiple in silico techniques. Initially, molecular docking against GABA and SERT receptors was performed to identify their potential against both targets. As a result, nearly two-thirds of the compounds demonstrated good affinity to GABA, even outperforming diazepam. Alternatively, only three compounds could reach scores more than that of paroxetine itself on the SERT. In both targets, compounds 5 and 15 were among the top-performing compounds with docking scores (-9.23 equally and -8.76Kcal/mole GABA for and -9.05 and -9.12 Kcal/mole for the SERT, respectively) surpassing those of the two drugs used as references (diazepam and paroxetine). They showed scores of -6.83 and -8.71 kcal/mole for GABA and the SERT, respectively and were promoted for further analysis. Subsequent analysis was done to evaluate their binding under normal physiological conditions for an extended time, reaching 50 ns. Both compounds demonstrated uniform and stable binding throughout the simulation time, compared to diazepam and paroxetine with RMSD values of approximately 2.40-2.90 Å and 2.10-2.50 Å for GABA and the SERT, respectively. Additionally, the RMSF behavior observed across the different simulations was consistent with both drugs. Further supporting evidence is their MM-GBSA energy calculation results, which enforced their stability as well. Finally, a DFT analysis was also performed to assess their stability, and both showed favorable energy parameters. In conclusion, this study demonstrates the potential of compounds 5 (lupulone) and 15 (chromen-4-one derivative) in targeting GABA and SERT receptors, while providing evidence and a basis for future clinical research.

Data availability statement

All data are included in the manuscript.

Author contributions

AB: conceptualization, investigation, writing-original draft, and writing-review and editing. ME: methodology, software, and writing-review and editing. AA-K: investigation, validation, and writing-review and editing. AH: data curation, formal analysis, and writing-review and editing. ER: validation, visualization, and writing-review and editing. MG: investigation, resources, validation, and writing-review and editing. MA: data curation, supervision, and writing-review and editing. AO: data curation, visualization, and writing-review and editing. JA: investigation, validation, and writing-review and editing. SS: conceptualization,

References

Belal, A., Elanany, M. A., Raafat, M., Hamza, H. T., and Mehany, A. B. M. (2022a). Calendula officinalis phytochemicals for the treatment of wounds through matrix metalloproteinases-8 and 9 (MMP-8 and MMP-9): *in silico* approach. *Nat. Product. Commun.* 17 (5), 1934578X2210988.48

Belal, A., Elanany, M. A., Santali, E. Y., Al-Karmalawy, A. A., Aboelez, M. O., Amin, A. H., et al. (2022). Screening a panel of topical ophthalmic medications against MMP-2 and MMP-9 to investigate their potential in keratoconus management. *Molecules* 27 (11), 3584. doi:10.3390/molecules27113584

Belal, A., Elsayed, A., Gharib, A. F., Ali Alqarni, M. A., Soliman, A. M., Mehany, A. B. M., et al. (2022b). Toward the discovery of SARS-CoV-2 main protease inhibitors: exploring therapeutic potentials of evodiamine and its derivatives, virtual screening,

investigation, validation, and writing-review and editing. ME: formal analysis, methodology, software, and writing-review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This research work was supported by Taif University, Saudi Arabia through the project number (TU-DSPP-2024-64). This research was also supported by the National Research Council of Science and Technology (NST) grant by the Korea government (MSIT) (No. CAP23011-100), KIST Institutional programs (2E33133) from Korea Institute of Science and Technology (KIST).

Acknowledgments

The authors extend their appreciation to Taif University, Saudi Arabia for supporting this work through the project number (TU-DSPP-2024-64). The authors also extend their appreciation to the National Research Council of Science and Technology (NST) grant by the Korea government (MSIT) (No. CAP23011-100), KIST Institutional programs (2E33133) from Korea Institute of Science and Technology (KIST).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

molecular docking, and molecular dynamic studies. *Nat. Product. Commun.* 17 (12), 1934578X2211430. doi:10.1177/1934578X221143082

Benkherouf, A. Y., Eerola, K., Soini, S. L., and Uusi-Oukari, M. (2020). Humulone modulation of GABAA receptors and its role in hops sleep-promoting activity. *Front. Neurosci.* 14, 594708. doi:10.3389/fnins.2020.594708

Bowers, K. J., Sacerdoti, F. D., Salmon, J. K., Shan, Y., Shaw, D. E., Chow, E., et al. (2006). "Molecular dynamics---Scalable algorithms for molecular dynamics simulations on commodity clusters," in *Proceedings of the 2006 ACM/IEEE conference on supercomputing* - SC '06 (New York, New York, USA: ACM Press), 84. doi:10.1145/1188455.1188544

Carbone, K., and Gervasi, F. (2022). An updated review of the genus Humulus: a valuable source of bioactive compounds for health and disease prevention. *Plants* 11 (24), 3434. doi:10.3390/plants11243434

Coleman, J. A., Green, E. M., and Gouaux, E. (2016). X-ray structures and mechanism of the human serotonin transporter. *Nature* 532 (7599), 334–339. doi:10.1038/ nature17629

Dassault Systèmes (2021). BIOVIA discovery studio visualizer.

Dimić, D. S., Marković, Z. S., Saso, L., Avdović, E. H., Đorović, J. R., Petrović, I. P., et al. (2019). Synthesis and characterization of 3-(1-((3,4-Dihydroxyphenethyl)amino) ethylidene)-chroman-2,4-dione as a potential antitumor agent. *Oxidative Med. Cell. Longev.* 2019, 1–12. doi:10.1155/2019/2069250

Gauthier, I., and Nuss, P. (2015). Anxiety disorders and GABA neurotransmission: a disturbance of modulation. *Neuropsychiatric Dis. Treat.* 165, 165. doi:10.2147/NDT. S58841

Gosmann, N. P., Costa, M. de A., Jaeger, M. de B., Motta, L. S., Frozi, J., Spanemberg, L., et al. (2021). Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: a 3-level network meta-analysis. *PLOS Med.* 18 (6), e1003664. doi:10. 1371/journal.pmed.1003664

Heinlein, A., Metzger, M., Walles, H., and Buettner, A. (2014). Transport of hop aroma compounds across Caco-2 monolayers. *Food Funct.* 5 (11), 2719–2730. doi:10. 1039/C3FO60675A

Hollister, L. E. (1981). Long-term use of diazepam. JAMA J. Am. Med. Assoc. 246 (14), 1568. doi:10.1001/jama.1981.03320140056031

Holmes, A., Murphy, D. L., and Crawley, J. N. (2003). Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression. *Biol. Psychiatry* 54 (10), 953–959. doi:10.1016/j.biopsych.2003. 09.003

Hrnčič, M. K., Španinger, E., Košir, I. J., Knez, Ž., and Bren, U. (2019). Hop compounds: extraction techniques, chemical analyses, antioxidative, antimicrobial, and anticarcinogenic effects. *Nutrients* 11 (2), 257. doi:10.3390/NU11020257

Inada, T., Nozaki, S., Inagaki, A., and Furukawa, T. A. (2003). Efficacy of diazepam as an anti-anxiety agent: meta-analysis of double-blind, randomized controlled trials carried out in Japan. *Hum. Psychopharmacol. Clin. Exp.* 18 (6), 483–487. doi:10. 1002/hup.510

Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J. F., Honig, B., Shaw, D. E., et al. (2004). A hierarchical approach to all-atom protein loop prediction. *Proteins Struct. Funct. Bioinforma.* 55 (2), 351–367. doi:10.1002/prot.10613

Jevtovic, V., Alshamari, A. K., Milenković, D., Dimitrić Marković, J., Marković, Z., and Dimić, D. (2023). The effect of metal ions (Fe, Co, Ni, and Cu) on the molecularstructural, protein binding, and cytotoxic properties of metal pyridoxalthiosemicarbazone complexes. *Int. J. Mol. Sci.* 24 (15), 11910. doi:10.3390/ jims241511910

Jupudi, S., Rajagopal, K., Murugesan, S., Kumar, B. K., Raman, K., Byran, G., et al. (2022). Identification of papain-like protease inhibitors of SARS CoV-2 through HTVS, molecular docking, MMGBSA and molecular dynamics approach. *South Afr. J. Bot.* 151, 82–91. doi:10.1016/j.sajb.2021.11.033

Kalueff, A. V., and Nutt, D. J. (2007). Role of GABA in anxiety and depression. Depress. Anxiety 24 (7), 495–517. doi:10.1002/da.20262

Kim, J. J., Gharpure, A., Teng, J., Zhuang, Y., Howard, R. J., Zhu, S., et al. (2020). Shared structural mechanisms of general anaesthetics and benzodiazepines. *Nature* 585 (7824), 303–308. doi:10.1038/s41586-020-2654-5

Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., et al. (2021). PubChem in 2021: new data content and improved web interfaces. *Nucleic Acids Res.* 49 (D1), D1388–D1395. doi:10.1093/nar/gkaa971

Knez Hrnčič, M., Španinger, E., Košir, I. J., Knez, Ž., and Bren, U. (2019). Hop compounds: extraction techniques, chemical analyses, antioxidative, antimicrobial, and anticarcinogenic effects. *Nutrients* 11 (2), 257. doi:10.3390/nu11020257

Korpelainen, H., and Pietiläinen, M. (2021). Hop (Humulus lupulus L.): traditional and present use, and future potential. *Econ. Bot.* 75 (3–4), 302–322. doi:10.1007/s12231-021-09528-1

Legler, C. R., Brown, N. R., Dunbar, R. A., Harness, M. D., Nguyen, K., Oyewole, O., et al. (2015). Scaled Quantum Mechanical scale factors for vibrational calculations using alternate polarized and augmented basis sets with the B3LYP density functional calculation model. *Spectrochimica Acta Part A Mol. Biomol. Spectrosc.* 145, 15–24. doi:10.1016/j.saa.2015.02.103

Lu, C., Wu, C., Ghoreishi, D., Chen, W., Wang, L., Damm, W., et al. (2021). OPLS4: improving force field accuracy on challenging regimes of chemical space. *J. Chem. Theory Comput.* 17 (7), 4291–4300. doi:10.1021/acs.jctc.1c00302

Michelini, S., Cassano, G., Frare, F., and Perugi, G. (2007). Long-Term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. *Pharmacopsychiatry* 29 (04), 127–134. doi:10.1055/s-2007-979558

Möhler, H. (2012). The GABA system in anxiety and depression and its therapeutic potential. *Neuropharmacology* 62 (1), 42–53. doi:10.1016/j.neuropharm.2011.08.040

Reilly, T. F. (1906). The therapeutics of lupulin. JAMA J. Am. Med. Assoc. XLVI (14), 1021. doi:10.1001/jama.1906.02510410023006

Sartori, S. B., and Singewald, N. (2019). Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. *Pharmacol. Ther.* 204, 107402. doi:10.1016/j.pharmthera.2019.107402

D. E. Shaw Research (2021). *Desmond Molecular Dynamics System*. New York, NY: Maestro-Desmond Interoperability Tools, Schrödinger.

Tronina, T., Popłoński, J., and Bartmańska, A. (2020). Flavonoids as phytoestrogenic components of hops and beer. *Molecules* 25 (18), 4201. doi:10. 3390/molecules25184201

Trott, O., and Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry* 31 (2). doi:10.1002/jcc.21334

Zangrossi, H., Del Ben, C. M., Graeff, F. G., and Guimarães, F. S. (2020). Serotonin in panic and anxiety disorders, 611-633. doi:10.1016/B978-0-444-64125-0.00036-0